The Investigative Journal’s weekly review of notable U.S. corporate disclosures filed with the Securities and Exchange Commission. All claims sourced to public records on SEC EDGAR and company investor relations channels.
Berkshire Hathaway’s First Post-Buffett 13F Reshapes the Oracle’s Portfolio
The most consequential institutional disclosure of the week-of-May filings cycle was Berkshire Hathaway’s quarterly Form 13F, lodged with the SEC on May 15, 2026, covering positions as of March 31. The filing was the first quarterly holdings report assembled under new chief executive Greg Abel, who took control of the conglomerate on January 1 after Warren Buffett’s transition to the chairman’s role.
Filings indicate Berkshire exited 16 positions during the first quarter, shrinking the equity book from roughly 40 names to 26 — one of the most aggressive single-quarter reductions in the company’s recent disclosure history, according to the 13F summary published by IndMoney. The Class A and Class C Alphabet stakes were the standout additions, with the Class A position growing by roughly 204 percent quarter-over-quarter. A new $2.6 billion stake in Delta Air Lines, equal to 39.8 million shares at quarter-end, marked Berkshire’s first material airline holding since the company famously dumped all four major U.S. carriers during the 2020 pandemic.
The top five holdings — Apple (21.99 percent), American Express (17.43 percent), Coca-Cola (11.56 percent), Bank of America (9.52 percent) and Chevron (6.64 percent) — remained recognizably Buffett-era, but the concentration of new buys around technology platforms and air travel suggests Abel is willing to redeploy cash at a pace Buffett rarely matched. The filing warrants further TIJ scrutiny because Berkshire’s 13F historically anticipates broader institutional rotation: Alphabet’s accumulation in particular may signal renewed long-duration conviction among value-oriented managers wary of AI-capex froth elsewhere in the megacap technology cohort.
West Pharmaceutical Discloses Material Ransomware Attack
On May 7, 2026, West Pharmaceutical Services filed an Item 1.05 Form 8-K determining that the company had experienced a material cybersecurity incident involving both data exfiltration and file-encrypting ransomware. Records indicate the intrusion was detected on May 4, with West taking systems offline globally for containment, retaining Palo Alto Networks’ Unit 42 for forensic work and notifying law enforcement.
The disclosure is significant for three reasons. First, it is one of the cleanest, fastest invocations of Item 1.05 since the SEC’s cybersecurity rule took effect in December 2023 — West met the four-business-day determination window without resorting to the national-security delay carve-out. Second, the company has not publicly identified the threat actor or confirmed whether protected health information was exposed, and no ransomware crew has claimed responsibility. As BleepingComputer noted, the absence of a public claim sometimes correlates with a paid ransom, though no public record confirms payment in this case. Third, West is a critical supplier of injectable drug-delivery components — vial stoppers, syringe plungers, and elastomer seals used across the pharmaceutical industry — meaning that any sustained disruption would have ripple effects across the U.S. drug supply chain. The company has since reported that core enterprise systems, manufacturing, and shipping have been restored. TIJ will monitor the company’s next 10-Q for quantified financial impact and any subsequent Form 8-K/A amendments.
Charles Schwab Shareholders Defy Board on Declassification
Charles Schwab Corporation held its 2026 annual meeting on May 21 and disclosed the results in a subsequent 8-K. Records indicate every director nominee was elected, Deloitte & Touche was ratified as auditor, and the advisory say-on-pay vote passed. The more interesting line item: a shareholder proposal to declassify the board of directors received a majority of votes cast in favor, but failed to clear the supermajority threshold required by the company’s governing documents.
The vote underscores a pattern flagged by Harvard Law’s Corporate Governance Forum for the 2026 season: even at large, well-regarded financial institutions, classified-board structures are losing legitimacy with institutional investors. When a majority of voted shares wants a change and the board’s own bylaws block it, the next governance pressure point is typically a withhold-vote campaign against the chair of the governance committee. Whether Schwab’s board engages with the result voluntarily or waits to be pushed will be a tell for how seriously incumbent boards take majority-but-not-supermajority signals across the rest of the season.
Six Say-on-Pay Failures Mid-Season — Arrowhead Pharmaceuticals at 41 Percent Support
Halfway through the 2026 proxy season, five Russell 3000 companies and one S&P 500 company have failed their advisory say-on-pay votes, according to the Boardroom Alpha scorecard. The headline failure is Arrowhead Pharmaceuticals, whose pay package secured only 41 percent shareholder support — a striking number even by the standards of pay revolts.
The average say-on-pay support level stands at 92.6 percent for the Russell 3000 and 91.3 percent for the S&P 500. Against that backdrop, ISS has been recommending against compensation packages where committees demonstrated limited responsiveness to prior failed votes. Simon Property Group drew an explicit ISS against recommendation on its say-on-pay proposal for that reason. Records also show that 18 directors at 14 companies received less than half of votes cast — a substantial uptick in protest votes targeting compensation committee chairs.
The deeper data point: median CEO compensation in the S&P 500 reached $29.4 million in fiscal 2025 — a 23.2 percent increase year-over-year, per the ISS-Corporate proxy season tracker. Pay-for-performance gaps and excessive security perquisites are the two themes ISS has cited most frequently in negative recommendations. TIJ will examine the full list of failing companies in a follow-up after the season closes.
Salesforce Discloses CAO Transition Alongside Record Q1 Results
Salesforce filed two 8-Ks on May 27 and May 28, 2026. The first announced Q1 fiscal 2027 results — earnings per share of $3.88 versus consensus of $2.96, a 31 percent beat. The second, separately filed, disclosed that Guy Wanger, 64, was appointed Chief Accounting Officer effective June 15, 2026. CAO transitions are routine, but they are also a category of Item 5.02 disclosure where filings indicate the timing matters: a new principal accounting officer arriving immediately after a record quarter is, in normal circumstances, unremarkable; arriving immediately before any sort of restatement risk would be a different story. There is no public record suggesting the latter at Salesforce. TIJ flags this only because Item 5.02 disclosures of senior accounting personnel are a category warranting ongoing pattern recognition across the index.
Microsoft, Vicor, and Qualys Insider Sales Run Through 10b5-1 Plans
Form 4 filings from the first two business days of June document a cluster of executive sales — all under pre-arranged Rule 10b5-1 plans, which limits inference about contemporaneous information advantage but does not eliminate it.
Microsoft’s Commercial CEO, Judson Althoff, sold 15,500 shares on June 1 at a weighted average of $460.988 per share — proceeds of approximately $7.15 million, according to the Form 4 disclosure. Qualys CEO Sumedh Thakar sold 13,200 shares the same day at prices in the low-$110s, and Vicor CEO Patrizio Vinciarelli disposed of 20,000 shares on June 2 at $317-$335 per share. All three transactions executed under 10b5-1 plans adopted months in advance, which under SEC rules requires a cooling-off period before the first trade.
The data point worth flagging is not any individual sale but the aggregate pattern: insider selling in megacap technology companies remains elevated relative to historical norms as broader indices test new highs. TIJ will track the Q2 cumulative selling figures against the Q1 baseline in next month’s column.
Board-Level Turmoil at Tempest Therapeutics and AIxCrypto Holdings
Two smaller-cap 8-K filings stand out as material governance events. Tempest Therapeutics disclosed on May 22 that three of its directors — Stephen Brady, Michael Raab, and Christine Pellizzari — resigned simultaneously, effective the same date. Simultaneous resignations of multiple independent directors are typically disclosed as a triggering event under Item 5.02(a) and historically correlate with either a strategic-alternatives review or a board-level disagreement requiring closer inspection. The filing itself does not indicate which.
Separately, AIxCrypto Holdings disclosed on May 21 the resignations of CFO and director Koti Meka and President Campbell Becher, with Meka’s director seat vacating immediately and his CFO role transitioning June 20. The combination of names — a cryptocurrency-themed micro-cap with concurrent senior officer turnover — is the kind of disclosure pattern TIJ will continue to watch given SEC Chairman Paul Atkins’ stated enforcement focus on rooting out fraud and remedying investor harm. Both filings warrant a deeper investigative look in coming weeks.
What Warrants Deeper TIJ Investigation
Three items from this week’s disclosure tape merit follow-up reporting. First, the Tempest Therapeutics triple resignation: simultaneous independent-director departures with no successor slate disclosed is a pattern Item 5.02 of Form 8-K was designed to surface, and TIJ will request the 8-K/A and any subsequent DEF 14A. Second, the West Pharmaceutical ransomware disclosure: the company has not yet quantified financial impact, and the supply-chain implications for U.S. injectable drug manufacturing warrant a dedicated piece. Third, the broader pattern emerging from 2026 proxy votes — boards defying majority-but-not-supermajority declassification votes, ISS escalating its scrutiny of pay-for-performance misalignment, and median CEO compensation rising 23 percent in a single year — suggests the proxy-advisory ecosystem and institutional investor base are entering a phase of more concentrated pressure on governance committees than at any point since the post-Sarbanes-Oxley reforms.
None of the disclosures discussed above constitutes a finding of wrongdoing. All claims are sourced to public records on SEC EDGAR and company investor relations channels. Companies named have a right of reply; TIJ welcomes corrections and additional context at editor@tij.news.
Sources: SEC EDGAR full-text search; West Pharmaceutical 8-K, May 7, 2026; Salesforce 8-K, May 28, 2026; Tempest Therapeutics 8-K, May 22, 2026; AIxCrypto Holdings 8-K, May 21, 2026; Boardroom Alpha 2026 Proxy Scorecard; ISS-Corporate Proxy Season 2026; Harvard Law Corporate Governance Forum.